New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Berlin: Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, have announced that they have entered into an ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Phase 1 trial of a pancreatic cancer vaccine targeting mutant KRAS shows strong immune responses, extended survival, and ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...